KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (ONC) Debt to Equity (2016 - 2025)

Historic Debt to Equity for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $0.4.

  • BeOne Medicines' Debt to Equity rose 3028.46% to $0.4 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.4, marking a year-over-year increase of 3028.46%. This contributed to the annual value of $0.31 for FY2024, which is 2197.44% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Debt to Equity is $0.4, which was up 3028.46% from $0.25 recorded in Q2 2025.
  • BeOne Medicines' 5-year Debt to Equity high stood at $0.4 for Q3 2025, and its period low was $0.1 during Q4 2021.
  • Moreover, its 5-year median value for Debt to Equity was $0.17 (2021), whereas its average is $0.21.
  • Its Debt to Equity has fluctuated over the past 5 years, first surged by 39227.03% in 2021, then crashed by 3762.14% in 2022.
  • Over the past 5 years, BeOne Medicines' Debt to Equity (Quarter) stood at $0.1 in 2021, then grew by 12.65% to $0.12 in 2022, then skyrocketed by 116.54% to $0.25 in 2023, then increased by 21.97% to $0.31 in 2024, then surged by 30.48% to $0.4 in 2025.
  • Its Debt to Equity was $0.4 in Q3 2025, compared to $0.25 in Q2 2025 and $0.26 in Q1 2025.